{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:03:36Z","timestamp":1790413416678,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Supportive Oncology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.suponc.2011.10.006","type":"journal-article","created":{"date-parts":[[2012,1,5]],"date-time":"2012-01-05T03:47:37Z","timestamp":1325735257000},"page":"155-159","source":"Crossref","is-referenced-by-count":34,"title":["Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients"],"prefix":"10.1016","volume":"10","author":[{"given":"Abhisek","family":"Swaika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Almyroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.suponc.2011.10.006_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2011.10.006_bib2","first-page":"S2","article-title":"The burden of herpes zoster and postherpetic neuralgia in the United States","volume":"107","author":"Weaver","year":"2007","journal-title":"J Am Osteopath Assoc"},{"issue":"suppl 2","key":"10.1016\/j.suponc.2011.10.006_bib3","first-page":"S2","article-title":"Herpes zoster overview: natural history and incidence","volume":"109","author":"Weaver","year":"2009","journal-title":"J Am Osteopath Assoc"},{"issue":"1","key":"10.1016\/j.suponc.2011.10.006_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/CMR.18.1.70-80.2005","article-title":"Preventing varicella-zoster disease","volume":"18","author":"Hambleton","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"10.1016\/j.suponc.2011.10.006_bib5","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1988.00380070065016","article-title":"Varicella-zoster infection in adult cancer patients","volume":"148","author":"Rusthoven","year":"1988","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.suponc.2011.10.006_bib6","first-page":"282","article-title":"Immunosuppression and infection in multiple myeloma","volume":"13","author":"Jacobson","year":"1986","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.suponc.2011.10.006_bib7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Schutt","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.suponc.2011.10.006_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2009.03.006","article-title":"Infections in patients with multiple myeloma","volume":"46","author":"Nucci","year":"2009","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1016\/j.suponc.2011.10.006_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"29","key":"10.1016\/j.suponc.2011.10.006_bib10","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.suponc.2011.10.006_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.suponc.2011.10.006_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLM.2008.n.031","article-title":"Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma","volume":"8","author":"Kim","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"issue":"9","key":"10.1016\/j.suponc.2011.10.006_bib13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.suponc.2011.10.006_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.20838","article-title":"The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients","volume":"82","author":"Tong","year":"2007","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.suponc.2011.10.006_bib15","first-page":"996","article-title":"Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice","volume":"90","author":"Wu","year":"2005","journal-title":"Haematologica"},{"issue":"9594","key":"10.1016\/j.suponc.2011.10.006_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9513","key":"10.1016\/j.suponc.2011.10.006_bib17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.suponc.2011.10.006_bib18","series-title":"National Comprehensive Cancer Network (NCCN)","year":"2010"},{"issue":"5","key":"10.1016\/j.suponc.2011.10.006_bib19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.suponc.2011.10.006_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","article-title":"Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib","volume":"9","author":"Pour","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"10.1016\/j.suponc.2011.10.006_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.suponc.2011.10.006_bib22","first-page":"488","article-title":"Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy [in Japanese]","volume":"50","author":"Hasegawa","year":"2009","journal-title":"Rinsho Ketsueki"},{"issue":"3","key":"10.1016\/j.suponc.2011.10.006_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.suponc.2011.10.006_bib24","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.suponc.2011.10.006_bib25","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells","volume":"65","author":"Altun","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.suponc.2011.10.006_bib26","doi-asserted-by":"crossref","first-page":"D200","DOI":"10.2741\/Kinchington","article-title":"Latency of varicella zoster virus; a persistently perplexing state","volume":"4","author":"Kinchington","year":"1999","journal-title":"Front Biosci"},{"issue":"10","key":"10.1016\/j.suponc.2011.10.006_bib27","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.4049\/jimmunol.0901596","article-title":"The proteasome inhibitor bortezomib enhances the susceptibility to viral infection","volume":"183","author":"Basler","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.suponc.2011.10.006_bib28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest"},{"issue":"5","key":"10.1016\/j.suponc.2011.10.006_bib29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.suponc.2011.10.006_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jama.1991.03460060079028","article-title":"Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection","volume":"265","author":"Kaplowitz","year":"1991","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.suponc.2011.10.006_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.1988.03410020067030","article-title":"Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection","volume":"260","author":"Mertz","year":"1988","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.suponc.2011.10.006_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminhematol.2009.03.004","article-title":"Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia","volume":"46","author":"Jancel","year":"2009","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.suponc.2011.10.006_bib33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1078155209350374","article-title":"Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?","volume":"16","author":"Dasanu","year":"2010","journal-title":"J Oncol Pharm Pract"}],"container-title":["The Journal of Supportive Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679411002503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679411002503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T20:54:57Z","timestamp":1561150497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544679411002503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1544679411002503"],"URL":"https:\/\/doi.org\/10.1016\/j.suponc.2011.10.006","relation":{},"ISSN":["1544-6794"],"issn-type":[{"value":"1544-6794","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}